EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Lenacapavir: A Novel Long-Acting Capsid Inhibitor for HIV

Marylee W Tailor iD, Elias B Chahine iD, David Koren iD, Elizabeth M Sherman iD

Annals of Pharmacotherapy · 2024-02 · 58 (2) · 185-195

DOI: 10.1177/10600280231171375 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Annals of Pharmacotherapy, online erschienen am 03.05.2023. Verfasst von Marylee W Tailor und 3 weiteren Autor:innen. Beteiligte Einrichtung: Nova Southeastern University, Fort Lauderdale, FL, USA. Hauptthemen laut MEDLINE: Anti-HIV Agents, HIV Infections. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To review the efficacy, safety, and role of lenacapavir (LEN) in the treatment of HIV-1 infection. Data Sources: A literature search was performed using PubMed and Google Scholar (through March 2023) with the search term LEN and GS-6207. Other resources included abstracts presented at recent conferences, the manufacturer’s Web site, and prescribing information. Study Selection and Data Extraction: All relevant articles, trial updates, and conference abstracts in the English language were included. Data Synthesis: Lenacapavir represents a new class of antiretrovirals (ARVs) with a novel mechanism of action as a capsid inhibitor and a unique twice-a-year subcutaneous administration schedule. Lenacapavir when combined with other ARVs has proven to benefit heavily treatment-experienced (HTE) patients with HIV-1 infection in achieving viral suppression and immune restoration. Relevance to Patient Care and Clinical Practice in Comparison With Existing Drugs: Lenacapavir is a new treatment option that patients who are HTE can consider adding as part of an ARV regimen.

Conclusions

Lenacapavir is an effective and well-tolerated option for HTE patients which is a valuable addition to the arsenal of ARVs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-HIV AgentsHIV InfectionsHumansCapsidAnti-Retroviral Agents

Stichwörter der Autor:innen

HIV capsid inhibitorantiretrovirallenacapavirlong-acting injectable

Substanzen

Anti-HIV AgentsAnti-Retroviral Agents

Autor:innen und Institutionen

  • Nova Southeastern University, Fort Lauderdale, FL, USA.
  • Lloyd L. Gregory School of Pharmacy, Palm Beach Atlantic University, Palm Beach, FL, USA.
  • Temple University Health System, Philadelphia, PA, USA.
  • Memorial Healthcare System, Hollywood, FL, USA.

ORCID-Profile: Marylee W Tailor, Elias B Chahine, David Koren, Elizabeth M Sherman

Zitieren

APA

Tailor, M. W., Chahine, E. B., Koren, D., & Sherman, E. M. (2024). Lenacapavir: A Novel Long-Acting Capsid Inhibitor for HIV. Annals of Pharmacotherapy, 58(2), 185-195. https://doi.org/10.1177/10600280231171375

Vancouver

Tailor MW, Chahine EB, Koren D, Sherman EM. Lenacapavir: A Novel Long-Acting Capsid Inhibitor for HIV. Annals of Pharmacotherapy. 2024;58(2):185-195. doi:10.1177/10600280231171375

BibTeX
@article{Tailor2024,
  author = {Tailor, Marylee W and Chahine, Elias B and Koren, David and Sherman, Elizabeth M},
  title = {Lenacapavir: A Novel Long-Acting Capsid Inhibitor for HIV},
  journal = {Annals of Pharmacotherapy},
  year = {2024},
  volume = {58},
  number = {2},
  pages = {185--195},
  doi = {10.1177/10600280231171375}
}
Kostenlos starten →